These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408 [TBL] [Abstract][Full Text] [Related]
4. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273 [TBL] [Abstract][Full Text] [Related]
5. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154 [TBL] [Abstract][Full Text] [Related]
6. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087 [TBL] [Abstract][Full Text] [Related]
7. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549 [TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Jerusalem GH; Beguin YP Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957 [TBL] [Abstract][Full Text] [Related]
9. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Shen YY; Kao A; Yen RF Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600 [TBL] [Abstract][Full Text] [Related]
10. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659 [TBL] [Abstract][Full Text] [Related]
11. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma]. Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282 [TBL] [Abstract][Full Text] [Related]
12. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514 [TBL] [Abstract][Full Text] [Related]
13. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808 [TBL] [Abstract][Full Text] [Related]
14. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348 [TBL] [Abstract][Full Text] [Related]
15. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418 [TBL] [Abstract][Full Text] [Related]
16. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093 [TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092 [TBL] [Abstract][Full Text] [Related]
18. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma. Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753 [TBL] [Abstract][Full Text] [Related]
20. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Ömür Ö; Baran Y; Oral A; Ceylan Y Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]